BRPI1015014A2 - composto, composição farmacêutica , e, método de tratamento de distúrbio(s) cognitivo(s) ou indicações com déficit(s) em cognição - Google Patents
composto, composição farmacêutica , e, método de tratamento de distúrbio(s) cognitivo(s) ou indicações com déficit(s) em cogniçãoInfo
- Publication number
- BRPI1015014A2 BRPI1015014A2 BRPI1015014A BRPI1015014A BRPI1015014A2 BR PI1015014 A2 BRPI1015014 A2 BR PI1015014A2 BR PI1015014 A BRPI1015014 A BR PI1015014A BR PI1015014 A BRPI1015014 A BR PI1015014A BR PI1015014 A2 BRPI1015014 A2 BR PI1015014A2
- Authority
- BR
- Brazil
- Prior art keywords
- cognitive impairment
- indications
- compound
- pharmaceutical composition
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16940909P | 2009-04-15 | 2009-04-15 | |
| PCT/SE2010/050404 WO2010120237A1 (en) | 2009-04-15 | 2010-04-14 | Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1015014A2 true BRPI1015014A2 (pt) | 2017-06-27 |
Family
ID=42981442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1015014A BRPI1015014A2 (pt) | 2009-04-15 | 2010-04-14 | composto, composição farmacêutica , e, método de tratamento de distúrbio(s) cognitivo(s) ou indicações com déficit(s) em cognição |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8178529B2 (pt) |
| EP (1) | EP2419425A4 (pt) |
| JP (1) | JP2012524063A (pt) |
| KR (1) | KR20120013951A (pt) |
| CN (1) | CN102459252A (pt) |
| AR (1) | AR076300A1 (pt) |
| AU (1) | AU2010237100A1 (pt) |
| BR (1) | BRPI1015014A2 (pt) |
| CA (1) | CA2761064A1 (pt) |
| MX (1) | MX2011010732A (pt) |
| RU (1) | RU2011140238A (pt) |
| TW (1) | TW201040169A (pt) |
| UY (1) | UY32562A (pt) |
| WO (1) | WO2010120237A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR058073A1 (es) * | 2005-10-03 | 2008-01-23 | Astrazeneca Ab | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos |
| WO2010120237A1 (en) * | 2009-04-15 | 2010-10-21 | Astrazeneca Ab | Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease |
| SG181896A1 (en) * | 2009-12-23 | 2012-07-30 | Map Pharmaceuticals Inc | Novel ergoline analogs |
| WO2012050517A1 (en) * | 2010-10-14 | 2012-04-19 | Astrazeneca Ab | Imidazole substituted pyrimidine having a high gsk3 inhibiting potency as well as pan-kinase selectivity |
| CA2838991A1 (en) | 2011-06-23 | 2012-12-27 | Map Pharmaceuticals, Inc. | Novel fluoroergoline analogs |
| EP2793580A4 (en) | 2011-12-19 | 2015-05-20 | Map Pharmaceuticals Inc | NEW DERIVATIVES OF ISO-ERGOLINE |
| WO2013095708A1 (en) | 2011-12-21 | 2013-06-27 | Map Pharmaceuticals, Inc. | Novel neuromodulatory compounds |
| US9012640B2 (en) | 2012-06-22 | 2015-04-21 | Map Pharmaceuticals, Inc. | Cabergoline derivatives |
| BR112014031945A2 (pt) * | 2012-06-22 | 2017-06-27 | Map Pharmaceuticals Inc | derivados de cabergolina |
| KR102413579B1 (ko) | 2015-10-06 | 2022-06-28 | 주식회사 에이치엘클레무브 | 운전자 편의 장치 및 그의 타겟 추정 방법 |
| HUE061898T2 (hu) * | 2017-09-08 | 2023-08-28 | Beigene Ltd | Imidazo[1,5-a]pirazin-származékok mint PI3Kdelta inhibitorok |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6200977B1 (en) | 1998-02-17 | 2001-03-13 | Tularik Inc. | Pyrimidine derivatives |
| GB9919778D0 (en) | 1999-08-21 | 1999-10-27 | Zeneca Ltd | Chemical compounds |
| GB0021726D0 (en) | 2000-09-05 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| GB0022438D0 (en) | 2000-09-13 | 2000-11-01 | Novartis Ag | Organic Compounds |
| MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
| ATE416175T1 (de) | 2001-02-20 | 2008-12-15 | Astrazeneca Ab | 2-arylaminopyrimidine zur behandlung von mit gsk3 in zusammenhang stehenden erkrankungen |
| SE0100569D0 (sv) | 2001-02-20 | 2001-02-20 | Astrazeneca Ab | New compounds |
| BR0213792A (pt) | 2001-11-01 | 2004-12-07 | Janssen Pharmaceutica Nv | Heteroaril aminas como inibidores de glicogênio sintase cinase 3beta (inibidores de gsk3) |
| US7442697B2 (en) * | 2002-03-09 | 2008-10-28 | Astrazeneca Ab | 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity |
| GB0205693D0 (en) * | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| US7361665B2 (en) | 2002-07-09 | 2008-04-22 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| GB0226583D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| GB0229581D0 (en) | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
| EP1611125A1 (en) | 2003-02-07 | 2006-01-04 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
| JP4808154B2 (ja) | 2003-03-13 | 2011-11-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとして有用な組成物 |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| BRPI0412351A (pt) | 2003-07-30 | 2006-09-05 | Cyclacel Ltd | derivados e piridilamino-pirimidina como inibidores de proteìna quinase |
| TW200528101A (en) | 2004-02-03 | 2005-09-01 | Astrazeneca Ab | Chemical compounds |
| WO2006064251A1 (en) | 2004-12-17 | 2006-06-22 | Astrazeneca Ab | 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors |
| GB0504753D0 (en) | 2005-03-08 | 2005-04-13 | Astrazeneca Ab | Chemical compounds |
| MX2008001428A (es) | 2005-07-30 | 2008-04-04 | Astrazeneca Ab | Compuestos de imidazolil-pirimidina para uso en el tratamiento de trastornos proliferativos. |
| CN101312977B (zh) * | 2005-09-22 | 2012-06-13 | 布里斯托尔-迈尔斯.斯奎布公司 | 用作激酶调节剂的稠合杂环化合物 |
| AR058073A1 (es) * | 2005-10-03 | 2008-01-23 | Astrazeneca Ab | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos |
| CN101321531A (zh) * | 2005-10-03 | 2008-12-10 | 阿斯利康(瑞典)有限公司 | 嘧啶衍生物在制备用于预防和/或治疗阿尔茨海默病的药物中的用途 |
| US20100063049A1 (en) | 2006-05-26 | 2010-03-11 | Clifford Jones | 2-carbocycloamino-4-imidazolylpyrimidines as agents for the inhbition of cell proliferation |
| TW200811169A (en) | 2006-05-26 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
| WO2007148070A1 (en) | 2006-06-21 | 2007-12-27 | Astrazeneca Ab | Chemical compounds |
| TW200815418A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds I |
| TW200815417A (en) * | 2006-06-27 | 2008-04-01 | Astrazeneca Ab | New compounds II |
| WO2008057930A2 (en) | 2006-11-02 | 2008-05-15 | Aestus Therapeutics, Inc. | Methods of treating neuropathic pain with retinoic acid receptor agonists |
| WO2009017454A1 (en) | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960 |
| WO2009017453A1 (en) | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 |
| WO2009017455A1 (en) | 2007-07-30 | 2009-02-05 | Astrazeneca Ab | A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor |
| WO2010120237A1 (en) * | 2009-04-15 | 2010-10-21 | Astrazeneca Ab | Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease |
-
2010
- 2010-04-14 WO PCT/SE2010/050404 patent/WO2010120237A1/en active Application Filing
- 2010-04-14 US US12/759,869 patent/US8178529B2/en not_active Expired - Fee Related
- 2010-04-14 BR BRPI1015014A patent/BRPI1015014A2/pt not_active IP Right Cessation
- 2010-04-14 TW TW099111649A patent/TW201040169A/zh unknown
- 2010-04-14 RU RU2011140238/04A patent/RU2011140238A/ru not_active Application Discontinuation
- 2010-04-14 CA CA2761064A patent/CA2761064A1/en not_active Abandoned
- 2010-04-14 EP EP10764741A patent/EP2419425A4/en not_active Withdrawn
- 2010-04-14 JP JP2012505856A patent/JP2012524063A/ja active Pending
- 2010-04-14 MX MX2011010732A patent/MX2011010732A/es not_active Application Discontinuation
- 2010-04-14 AR ARP100101250A patent/AR076300A1/es unknown
- 2010-04-14 KR KR1020117024168A patent/KR20120013951A/ko not_active Application Discontinuation
- 2010-04-14 UY UY0001032562A patent/UY32562A/es not_active Application Discontinuation
- 2010-04-14 AU AU2010237100A patent/AU2010237100A1/en not_active Abandoned
- 2010-04-14 US US13/264,529 patent/US20120077813A1/en not_active Abandoned
- 2010-04-14 CN CN2010800265500A patent/CN102459252A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010237100A1 (en) | 2011-10-27 |
| AR076300A1 (es) | 2011-06-01 |
| KR20120013951A (ko) | 2012-02-15 |
| EP2419425A4 (en) | 2012-08-29 |
| RU2011140238A (ru) | 2013-05-20 |
| TW201040169A (en) | 2010-11-16 |
| WO2010120237A1 (en) | 2010-10-21 |
| JP2012524063A (ja) | 2012-10-11 |
| CA2761064A1 (en) | 2010-10-21 |
| CN102459252A (zh) | 2012-05-16 |
| EP2419425A1 (en) | 2012-02-22 |
| UY32562A (es) | 2010-11-30 |
| US20100267723A1 (en) | 2010-10-21 |
| US8178529B2 (en) | 2012-05-15 |
| US20120077813A1 (en) | 2012-03-29 |
| MX2011010732A (es) | 2011-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1015014A2 (pt) | composto, composição farmacêutica , e, método de tratamento de distúrbio(s) cognitivo(s) ou indicações com déficit(s) em cognição | |
| BRPI1013705A2 (pt) | compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica | |
| BRPI1007477A2 (pt) | método, e, composição de tratamento de poço | |
| BRPI1010798A2 (pt) | fechamento, aparelho de retenção, e método de uso do mesmo | |
| BR112012013175A2 (pt) | 2-amino-5,5-diflúor-5,6-di-hidro-4h-oxazinas como inibidores de bace 1 e/ou bace 2 | |
| BRPI1013559A2 (pt) | compostos, composição farmacêutica, método de tratamento de doença ou condição associada à função trpa1 e respectivos usos | |
| BR112012022878A2 (pt) | composto, composição farmacêutica, uso do compostos e método de tratamento | |
| BRPI1014864A2 (pt) | "implante de processos espinhosos e métodos associados" | |
| BR112012006644A2 (pt) | composto,método de tratamento de um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal, composição farmacêutica, uso de um composto e kit | |
| BRPI0814941A2 (pt) | Composição de tratamentode semente, e, método de tratamento de semente. | |
| BRPI0918693A2 (pt) | dispositivos para amostragem e métodos para concentração de microorganismos | |
| BRPI0919288A2 (pt) | teriapia de combinação para tratamento de diabetes e condições relacionadas. | |
| BR112012008048A2 (pt) | dispositivos eletrocrômicos, montagens que incorporam dispositivos eletrocrômicos, e/ou métodos de fabricação dos mesmos | |
| BR112012006640A2 (pt) | composto, composição farmacêutica, método de tratamento de um distúrbio cognitivo, distúrbiopsocótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal e kit | |
| BR112012006648A2 (pt) | composto,método de tratamento de um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal, composição farmacêutica e kit | |
| BR112013011737A2 (pt) | composto, uso de um composto composição farmacêutica, e, método de tratamento ou prevenção de uma infecção por hiv | |
| FI20095553A (fi) | Jätteenkäsittelyjärjestelmä ja menetelmä | |
| BRPI1007996A2 (pt) | fluido de tratamento, e, método | |
| BRPI1008628A2 (pt) | método de tratamento ou prevenção de arritmia cardíaca em um indivíduo | |
| BRPI0913739A2 (pt) | Composição líquida, método, e, uso de composição | |
| BR112012000025A2 (pt) | polipeptídos e processo de tratamento. | |
| BR112012020585A2 (pt) | composto, composição farmacêutica e método de tratamento de um distúrbio mediado por tirosina quinase | |
| BR112013009294A2 (pt) | componente dental, fixação dental, conjunto de implante dental e sistema de implante dental | |
| BRPI0917321A2 (pt) | prevenção, tratamento e diagnóstico de infecção por p. gingivalis | |
| BRPI1006145A2 (pt) | "composição e método para tratamento de diabetes". |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |